Ag-Specific Type 1 CD8 Effector Cells Enhance Methotrexate-Mediated Antitumor Responses by Modulating Endogenous CD49b-Expressing CD4 and CD8 T Effector Cell Subpopulations Producing IL-10

REFERENCES

• Almeida A. R. M., Rocha B., Freitas A. A., Tanchot C. Homeostasis of T cell numbers: from thymus production to peripheral compartmentalization and the indexation of regulatory T cells. Sem. Immunol 2005; 17: 239–249
   PubMedGoogle Scholar
• Arase H., Saito T., Phillips J. H., Lanier L. L. Cutting Edge: The mouse NK cell-associated antigen recognized by DX5 monoclonal antibody is CD49b (alpha2 Integrin, very late antigen-2). J. Immunol 2001; 167: 1141–1144
   Google Scholar
• Awwad M., North R. J. Cyclophosphamide (CY)-facilitated adoptive immunotherapy of a CY- resistant tumor. Evidence that CY permits the expression of adoptive T cell-mediated immunity by removing suppressor T cells rather than by reducing tumor burden. Immunology 1988; 65: 87–92
   PubMed Web of Science ®Google Scholar
• Barrat F. J., Cua D. J., Boonstra A., Richards D. F., Crain C., Savelkoul H. F., de Waal-Malefyt R., Coffman R. L., Hawrylowicz C. M., O'Garra A. In vitro generation of IL-10-producing regulatory CD4 T cells is induced by immunosuppressive drugs and inhibited by Th1 and Th2-inducing cytokines. J. Exp. Med. 2002; 195: 603–615
   PubMed Web of Science ®Google Scholar
• Bishop M. R., Fowler D. H., Marchigiani D., Castro K., Kasten-Sportes C., Steinberg S. M., Gea-Banacloche J. C., Dean R., Chow C. H., Carter C., Read E. J., Leitman S., Gress R. Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer. J. Clin. Oncol 2004; 22: 3886–3894
   PubMed Web of Science ®Google Scholar
• Carter L. L., Dutton R. W. Cutting edge: Relative perforin and Fas-mediated lysis in T1 and T2 CD8 effector populations. J. Immunol 1995; 155: 1028–1031
   PubMed Web of Science ®Google Scholar
• Casares N., Pequignot M. O., et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J. Exp. Med 2005; 202: 1691–1701
   PubMed Web of Science ®Google Scholar
• Cerwenka A., Morgan T. M., Dutton R. W. Naïve, effector and memory CD8 T cells in protection against pulmonary influenza virus infection: Homing properties rather than initial frequencies are crucial. J. Immunol 1999; 163: 5535–5543
   PubMed Web of Science ®Google Scholar
• Chabner B. A., Roberts T. G., Jr. Chemotherapy and the war on cancer. Nat. Rev. Cancer 2005; 5: 65–72
   PubMed Web of Science ®Google Scholar
• Charbonnier L. M., van Duivenvoorde L.M., Apparailly F., Cantos C., Han W. G. H., Noel D., Duperray C., Huizinga T. W. J., Toes R. E. M., Jorgensen C., Louis-Plence P. Immature dendritic cells suppress collagen-induced arthritis by in vivo expansion of CD49b regulatory T cells. J. Immunol 2006; 177: 3806–3813
   PubMed Web of Science ®Google Scholar
• Chess L., Jiang H. Resurrecting CD8 suppressor T cells. Nature Immunol 2004; 5: 469–349
   PubMed Web of Science ®Google Scholar
• Croft M., Carter L. L., Swain S. L., Dutton R. W. Generation of polarized antigen specific CD8 effector populations: Reciprocal actions of IL-4 and IL-12 in promoting type 2 versus type 1 cytokine profiles. J. Exp. Med 1994; 180: 1715–1794
   PubMed Web of Science ®Google Scholar
• Crowe N. Y., Coquet J. M., Berzins S. P., Kyparissoudis K., Keating R., Pellicci D. G., Hayakawa Y., Godfrey D. I., Smyth M. J. Differential antitumor immunity mediated by NKT cell subsets in vivo. J. Expt. Med 2005; 202: 1279–1288
   PubMed Web of Science ®Google Scholar
• Curiel T. J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., Evdemon-Hogan M., Conejo-Garcia J. R., Zhang L., Burrow M., Zhu Y., Wei S., Kryczek I., Daniel B., Gordon B., Myers L., Luckner A., Disis M. L., Knutson K. L., Chen L., Zou W. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med 2004; 10: 942–949
   PubMed Web of Science ®Google Scholar
• Dobrzanski M. J., Reome J. B., Dutton R. W. Type 1 and type 2 CD8 effector T cell subpopulations promote long-term tumor immunity and protection to progressively growing tumors. J. Immunol 2000; 164: 916–925
   PubMed Web of Science ®Google Scholar
• Dobrzanski M. J., Reome J. B., Hollenbaugh J. A., Dutton R. W. Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous Type 1 antitumor responses. J. Immunol 2004a; 172: 1380–1391
   PubMedGoogle Scholar
• Dobrzanski M. J., Reome J. B., Hylind J. C., Rewers-Felkins K. A. CD8-mediated type 1 antitumor responses selectively modulate endogenous differentiated and nondifferentiated T cell localization, activation and function in progressive breast cancer. J. Immunol 2006; 177: 8191–8201
   PubMed Web of Science ®Google Scholar
• Dobrzanski M. J., Reome J. B., Hollenbaugh J. A., Hylind J. C., Dutton R. W. Effector cell-derived lymphotoxin-α and FasL, but not perforin, promote Tc1 and Tc2 effector cell-mediated Tumor Therapy in established pulmonary metastases. Cancer Res 2004b; 64: 406–413
   PubMedGoogle Scholar
• Dudley M. E., Wunderlich J. R., Robbins J. R., Yang J. C., Hwu P., Schwartzentruber D. J., Topalian S. L., Sherry R., Restifo N. P., Hubicki A. M., Robinson M. R., Raffeld M., Duray P., Seipp C. A., Rogers-Freezer L., Morton K. E., Mavroukakis S. A., White D. E., Rosenberg S. A. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298: 850–854
   PubMed Web of Science ®Google Scholar
• Eberl G., Lees R., Smiley S. T., Taniguchi M., Grusby M. J., MacDonald H. R. Tissue-specific segregation of CD1d-dependent and CD1d-independent NK T cells. J. Immunol 1999; 162: 6410–6419
   PubMed Web of Science ®Google Scholar
• Endharti A. T., Rifa'I M., Shi Z., Fukuoka Y., Nakahara Y., Kawamoto Y., Takeda K., Isobe K., Suzuki H. Cutting Edge: CD8 CD122 regulatory T cells produce IL-10 to suppress IFN-γ production and proliferation of CD8 T cells. J. Immunol 2005; 175: 7093–7097
   PubMed Web of Science ®Google Scholar
• Garrod K. R., Wei S. H., Parker I., Cahalan M. D. Natural killer cells actively patrol peripheral lymph nodes forming stable conjugates to eliminate MHC-matched targets. PNAS. 2007; 104: 12081–12086
   Google Scholar
• Godfrey D. I., MacDonald H. R., Kronenberg M., Smyth M. J., Van Kaer L. NKT cells: what's in a name?. Nat. Rev. Immunol. 2004; 4: 231–237
   PubMed Web of Science ®Google Scholar
• Gonzalez A., Andre-Schmutz I., Carnaud C., Mathis D., Benoist C. Damage control, rather than unresponsiveness, effected by protective DX5 T cells in autoimmune diabetes. Nat. Immunol 2001; 2: 1117–1125
   Google Scholar
• Groux H., O'Garra A., Bigler M., Rouleau M., de Vries J., Roncarolo M. G. Generation of a novel regulatory CD4 T cell population which inhibits antigen-specific T cell responses. Nature 1997; 389: 737–742
   PubMed Web of Science ®Google Scholar
• Hammond K. J. L., Pelikan S. B., Crowe N. Y., Randle-Barrett E., Nakayama T., Taniguchi M., Smyth M. J., van Driel I. R., Scollay R., Baxter A. G., Godfrey D. I. NKT cells are phenotypically and functionally diverse. Eur. J. Immunol 1999; 29: 3768–3781
   PubMed Web of Science ®Google Scholar
• Jiang H., Chess L. Regulation of immune responses by T cells. N. Engl J. Med 2006; 354: 1166–1176
   PubMed Web of Science ®Google Scholar
• Jolivet J., Cowan K. H., Curt G. A., Clendeninn N. J., Chabner B. A. The pharmacological and clinical use of methotrexate. N. Engl. J. Med 1983; 309: 1094–1104
   PubMed Web of Science ®Google Scholar
• Joyee A. G., Qiu H., Wang S., Fan Y., Bilenki L., Yang X. Distinct NKT cell subsets are induced by different Chlamydia species leading to differential adaptive immunity and host resistance to the infections. J. Immunol 2007; 178: 1048–1058
   Google Scholar
• Juliano R. L., Haskill S. Signal transduction from the extracellular matrix. J. Cell Biol 1993; 120: 577–585
   PubMed Web of Science ®Google Scholar
• Kassiotis G., Gray D., Kiafard Z., Zwirner J., Stockinger B. Functional specialization of memory Th cells revealed by expression of integrin CD49b. J. Immunol 2006; 177: 968–975
   Google Scholar
• Lake R. A., Robinson B. W. S. Immunotherapy and chemotherapy-a practical partnership. Nat Rev. Cancer 2005; 5: 397–405
   PubMed Web of Science ®Google Scholar
• Longley D. B., Harkin D. P., Johnson P. G. 5-fluorouracil: mechanisms of action and clinical strategies. Nat. Rev. Cancer 2003; 3: 330–338
   PubMed Web of Science ®Google Scholar
• Maggi E., Manetti R., Annunziato F., Cosmi L., Giudizi M. G., Biagiotti R., Galli G., Zuccati G., Romagnani S. Functional characterization and modulation of cytokine production by CD8 T cells from human immunodeficiency virus-infected individuals. Blood 1997; 89: 3672–3679
   Google Scholar
• Mainiero F., Gismondi A., Soriani A., Cippitelli M., Palmieri G., Jacobelli J., Piccoli M., Frati L., Santoni A. Integrin-mediated ras-extracellular regulated kinase (ERK) signaling regulates interferon gamma production in human natural killer cells. J. Exp. Med 1998; 188: 1267–1275
   PubMed Web of Science ®Google Scholar
• Marincola F. M., Wang E., Herlyn M., Seliger B., Ferrone S. Tumors as elusive targets of T cell- based active immunotherapy. Trends Immunol 2003; 24: 334–341
   Web of Science ®Google Scholar
• Messman R. A., Allegra C. J. Cancer chemotherapy and biotherapy, B. A. Chabner, D. Longo. Lippincott Williams and Wilkins, Philadelphia, PA 2001; 139–184
   Google Scholar
• Micheau O., Solary E., Hammann A., Martin F., Dimanche-Boitrel M. T. Sensitization of cancer cells treated with cytoablative drugs to Fas-mediated cytotoxicity. J. Natl. Cancer Inst 1997; 89: 783–786
   PubMedGoogle Scholar
• Minchinton A. I., Tannock I. F. Drug penetration in solid tumors. Nat. Rev. Cancer 2006; 6: 583–592
   PubMed Web of Science ®Google Scholar
• Mizoguchi H., O'shea J.J., Longo D. L., Loeffler C. M., McVicar D. W., Ochoa A. C. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 1992; 258: 1795–1798
   PubMed Web of Science ®Google Scholar
• Moodycliffe A. M., Ngheim D., Clydesdale G., Ullrich S. E. Immune suppression and skin cancer development: regulation by NKT cells. Nat. Immunol 2000; 1: 521–525
   PubMed Web of Science ®Google Scholar
• Moore K. W., de Waal Malefyt R., Coffman R. L., O'Garra A. IL-10 and the IL-10 receptor. Annu. Rev. Immunol 2001; 19: 683–765
   PubMed Web of Science ®Google Scholar
• Morgan J. D., Liblau R., Scott B., Fleck S., McDevitt H. O., Sarvetnick N., Lo D., Sherman L. A. CD8 T cell mediated spontaneous diabetes in neonatal mice. J. Immunol 1996; 157: 978–986
   Google Scholar
• Nanni P., de Giovanni C., Lollini P. L., Prodi G. TS/A: a new metastasizing cell line from BALB/c spontaneous mammary adenocarcinoma. Clin. Exp. Metastasis 1983; 4: 373–380
   Google Scholar
• North R. J. Downregulation of the antitumor immune response. Adv. Cancer Res 1985; 45: 1–43
   PubMed Web of Science ®Google Scholar
• Nowak A. K., Robinson B. W. S., Lake R. A. Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res 2003; 63: 4490–4496
   PubMed Web of Science ®Google Scholar
• Pellicci D. G., Hammond K. J. L., Coquet J., Kyparissoudis K., Brooks A. G., Kedzierska K., Keating R., Turner S., Berzins S., Smyth M. J., Godfrey D. I. DX5/CD49b-positive T cells are not synonymous with CD1d-dependent NKT cells. J. Immunol 2005; 175: 4416–4425
   Google Scholar
• Piccirillo C. A., Shevach E. M. Naturally occurring CD4/CD25 immunoregulatory T cells: central players in the arena of peripheral tolerance. Sem Immunol 2004; 16: 81–88
   PubMed Web of Science ®Google Scholar
• Rahmoun M., Foussat A., Groux H., Pene J., Yssel H., Chanez P. Enhanced frequency of CD18- and CD49b-expressing T cells in peripheral blood of asthmatic patients correlates with disease severity. Int. Arch. Allergy Immunol 2006; 140: 139–149
   PubMed Web of Science ®Google Scholar
• Restifo N. P. Building better vaccines: how apoptotic cell death can induce inflammation and activate innate and adaptive immunity. Curr. Opin. Immunol 2000; 12: 597–603
   PubMed Web of Science ®Google Scholar
• Rosenberg S. A. Shedding light on immunotherapy for cancer. N. Engl. J. Med 2004; 350: 1461–1465
   PubMed Web of Science ®Google Scholar
• Sad S., Marcotte R., Mosmann T. R. Cytokine induced differentiation of precursor mouse CD8 T cells into cytotoxic CD8 T cells secreting th1 or th2 cytokines. Immunity 1995; 2: 271–280
   PubMed Web of Science ®Google Scholar
• Salgame P., Abrams J. S., Clayberger C., Goldstein H., Convit J., Modlin R. L., Bloom B. Differing lymphokine profiles of functional subsets of human CD4 and CD8 T cell clones. Science 1991; 254: 279–283
   PubMed Web of Science ®Google Scholar
• Scheffer S. R., Nave H., Korangy F., et al. Apoptotic, but not necrotic, tumor cell vaccines induce a potent immune response in vivo. Int J. Cancer 2003; 103: 205–211
   PubMed Web of Science ®Google Scholar
• Schwartz M. A., Schaller M. D., Ginsberg M. H. Integrins: emerging paradigms of signal transduction. Annu. Rev. Cell Dev. Biol 1995; 11: 549–599
   PubMed Web of Science ®Google Scholar
• Sheu B., Lin R., Lien H., Ho H., Hsu S., Huang S. Predominant Th2/Tc2 polarity of tumor infiltrating lymphocytes in human cervical cancer. J. Immunol 2001; 167: 2972–2982
   PubMed Web of Science ®Google Scholar
• Shi Y., Evans J. E., Rock K. L. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003; 425: 516–521
   PubMed Web of Science ®Google Scholar
• Singh S., Ross S. R., Acena M., Rowley D. A., Schreiber H. Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells. J. Exp. Med 1992; 175: 139–146
   PubMed Web of Science ®Google Scholar
• Smyth M. J., Hayakawa Y., Tqakeda Y., Yagita H. New aspects of natural-killer cell surveillance and therapy of cancer. Nat. Rev. Cancer 2002; 2: 850–861
   PubMed Web of Science ®Google Scholar
• Smyth M. J., Teng M. W. L., Swann J., Kyparissoudis K., Godfrey D. I., Hayakawa Y. CD4 CD25 T regulatory cells suppress NK cell-mediated immunotherapy of cancer. J. Immunol 2006; 176: 1582–1587
   PubMed Web of Science ®Google Scholar
• Surh C. D., Sprent J. Regulation of mature T cell homeostasis. Sem. Immunol 2005; 17: 183–191
   PubMed Web of Science ®Google Scholar
• Taieb J., Chaput N., Schartz N., Roux S., Novault S., Menard C., Ghiringhelli F., Terme M., Carpentier A. F., Darrasse-Jese G., Lemonnier F., Zitvogel L. Chemotherapy of tumors: Cyclophosphamide synergizes with exosome based vaccines. J. Immunol 2006; 176: 2722–2729
   PubMed Web of Science ®Google Scholar
• Vieira P. L., Christensen J. R., Minaee S., O'Neil E. J., Barrat F. J., Boonstra A., Barthlott T., Stockinger B., Wraith D. C., O'Garra A. IL-10 secreting regulatory T cells do not express Foxp3 but have comparable regulatory function to naturally occurring CD4 CD25 regulatory T cells. J. Immunol 2004; 172: 5986–5993
   PubMed Web of Science ®Google Scholar
• Vukmanovic-Stejic M., Vyas B., Gorak-Stolinska P., Noble A., Kemeny D. M. Human Tc1 and Tc2/Tc0 CD8 T cell clones display distinct cell surface and functional phenotypes. Blood 2000; 95: 231–237
   PubMed Web of Science ®Google Scholar
• Woo E. Y., Chu C. S., Goletz T. J., Schlienger K., Yeh H., Coukos G., Rubin S. C., Kaiser L. R., June C. H. Regulatory CD4CD25 T cells in tumors from patients with early stage non-small cell lung cancer and late stage ovarian cancer. Cancer Res 2001; 61: 4766–4774
   PubMed Web of Science ®Google Scholar
• Yee C., Thompson J. A., Bryd D., Ridell S. R., Roche P., Celis E., Greenberg P. D. Adoptive T cell therapy using antigen-specific CD8 T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci 2002; 99: 16168–16176
   PubMed Web of Science ®Google Scholar
• Yee C., Thompson J. A., Roche P., Bryd D. R., Lee P. P., Piepkorn M., Kenyon K., Davis M. M., Riddell S. R., Greenberg P. D. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of T cell-mediated vitiligo. J. Exp. Med 2000; 192: 1637–1643
   PubMed Web of Science ®Google Scholar
• Zhang C., Zhang J., Tian Z. The regulatory effects of natural killer cells: Do NK-reg cells” exist. Cell. Mol. Immunol 2006; 3: 241–254
   PubMed Web of Science ®Google Scholar